All News

There are unique complexities when implementing bispecific antibodies, including site of care considerations, monitoring, and management of adverse events.

These FDA-approved therapies are used to treat lymphoma after 2 or more lines of therapy and represent significant advancements in the treatment of lymphoma.

FDA-approved BiTE therapies for relapsed/refractory multiple myeloma show promising response rates, offering off-the-shelf alternatives to CAR T therapy.

The approval expands the prior indication of idecabtagene vicleucel (Abecma; Bristol Myers Squibb), which will make the drug available to patients in earlier lines.

The Librexia program includes 3 concurrent clinical trials, investigating milvexian’s use for ischemic stroke, acute coronary syndrome, and atrial fibrillation

James Shehan discusses the growth of the GLP-1 receptor agonist market for medicated-assisted weight loss.

Despite being a Schedule I drug, cannabis is increasingly used in oncology for symptom management, although data remains limited.

Lisa Janssen Carlson, PharmD, BCOP, discusses some background and history of regulations for the conduct of clinical trials.

Pharmacy Times will be at the American Association of Psychiatric Pharmacists (AAPP) Annual Meeting in Orlando, Florida from April 7 to April 10, 2024.

Precision medicine revolutionized NSCLC treatment, targeting specific mutations like KRAS G12C with therapies such as adagrasib to improve patient outcomes.

Several studies on valerian have been conducted in the past 50 years for indications varying from insomnia, anxiety, restless leg syndrome, headaches, and more.

MDMA-assisted therapy and psilocybin currently lead the way with potential approvals by the FDA.

The expanded role of oncology pharmacists includes the opportunity to work in ambulatory settings, infusion centers, delivery of specialized in pharmacy services, evaluation of investigational new drugs, and manager roles in drug chain supply and in coordination of care.

Bimekizumab-bkzx (Bimzelx; Union Chimique Belge) is a humanized monoclonal immunoglobulin G1 antibody that inhibits interleukin (IL)-17A and IL-17F.

Taking steps to improve front-end sales takes some time and out-of-the-box thinking, but it can prove profitable and improve word-of-mouth recommendations.

Despite the positive results demonstrated in a prior phase 2 trial, AMX0035 failed to meet the phase 3 trial’s primary end point in treating patients with amyotrophic lateral sclerosis.

New indications include Staphylococcus aureus bloodstream (SAB) infections, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia.

This short story, illustrated by Roth, portrays pharmacists in a variety of settings and was written with the intent to introduce the career in a fun and understandable way for children and inspire kids to pursue their dreams.

The results indicate the need for targeted policies so that biosimilar competition can increase cost savings and affordability for patients with commercial insurance.

Investigators also found that African American and White veterans had different risk factors for re-hospitalization post-stroke.

This medication is associated with a number of adverse effects, such as gastrointestinal upset and peripheral neuropathies, that may be mitigated by less frequent dosing.

This holistic approach to healing, grounded in harnessing the therapeutic properties of plants, serves as a bridge between centuries-old traditional wisdom and modern scientific practices.

Unlike conventional monoclonal antibodies, BsAbs possess dual binding domains that target 2 distinct antigens simultaneously.

Investigators compared the copy number alterations of patients who were male and female using 16 cancer types in The Cancer Genome Atlas Program.

Study outcomes demonstrated that 80 HER2-postive BTC individuals enrolled in Cohort 1 of the study achieved a confirmed objective response rate of 41.3%

Advanced analytics will continue to make health care more accessible and empower pharmacists with the ability to personalize treatments.

A study about modifiable risk factors on a “weak spot” in the brain network found that diabetes, pollution, and alcohol were most likely to contribute to dementia disorders.

The decision follows phase 3 trial results that demonstrated improved progression-free survival and confirmed the safety of Dato-DXd in patients with breast cancer.